We gratefully acknowledge Hui-Hsing Wong (ASPE) and Amber Jessup (ASPE) for their leadership, guidance, and input throughout this study. We also would like to thank Edward Cox (FDA) and Michael Lanthier (FDA) for their insightful comments, advice, and guidance. IMS Health provided the sales data for the analysis of antibacterials designed to treat different indications. We would like to thank Laura Governale (FDA), Patty Greene (FDA), Grace P. Chai (FDA), Katrina S. Garry (FDA), and Psachal Calloway (FDA) for accommodating our data requests and answering our questions.
Many people involved in clinical research, including pharmaceutical/biopharmaceutical company representatives, academic researchers, and industry experts, provided valuable information for the study. We are grateful to all of them for sharing their expertise and experiences with us. Finally, we would like to thank the workshop participants at the Brookings Institute meeting on antibacterials titled Incentives for Change: Addressing the Challenges in Antibacterial Drug Development for their input.